Overview

IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD

Status:
Unknown status

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

This is a prospective, single-blind, randomized study to evaluate intravitreal aflibercept injection (IAI) versus sham as prophylaxis against conversion to neovascular age-related macular degeneration (AMD) in "high-risk" subjects.

Phase:

Phase 2

Details

Lead Sponsor:

Jeffrey S Heier

Collaborator:

Regeneron Pharmaceuticals

Treatments:

Aflibercept